| Authors: |
Overdijk MB; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Strumane K; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Beurskens FJ; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Ortiz Buijsse A; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Vermot-Desroches C; iDD biotech, Lyon, France., Vuillermoz BS; iDD biotech, Lyon, France., Kroes T; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., de Jong B; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Hoevenaars N; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Hibbert RG; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Lingnau A; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Forssmann U; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Schuurman J; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Parren PWHI; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands., de Jong RN; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Breij ECW; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton. ebj@genmab.com. |
